Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medical Device Giants Fight For Basic-Level Market

This article was originally published in PharmAsia News

Executive Summary

At the recent 60th China International Medical Equipment Fair in Suzhou, medical device giants gave emphasis to products suitable for small and medium health care institutions. GE Healthcare used the event to debut its new products specially developed for rural and community health care services. Its R&D center in China will add 20 new recruits to the existing 100 researchers to develop products for the grass root market. Meanwhile, Siemens highlighted its product line,which is being deployed in the rural market. Hitherto the main market of local medical device manufacturers, basic-level business is seeing increasing competitive pressure from MNCs. Technology represents the weak link for the Chinese companies as innovation needs to be a continuous process. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067116

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel